Key Highlights

  • The FDA issued a third Complete Response Letter for reproxalap in dry eye disease on March 17, 2026, citing inconsistent efficacy data.
  • Shares fell roughly 70% on the news, dropping from about $4.23 to near $1.37 following the rejection.
  • Aldeyra held roughly $70 million in cash as of December 31, 2025, which management says funds operations into 2028.

Few small-cap biotechs have swung as violently on a single regulatory decision as Aldeyra Therapeutics (NASDAQ: ALDX). The dry-eye specialist entered 2026 chasing what would have been its first drug approval, only to absorb another rejection from the U.S. Food and Drug Administration in March. With shares now trading near a dollar and a half, the modest slip flagged in ALDX's latest session is a small footnote to a much larger story about Regulatory Risk and a stalled path to market.

Company and Latest Development

Aldeyra Therapeutics is a clinical-stage biotechnology company built around reactive aldehyde species (RASP) modulation, an anti-inflammatory approach. Its lead candidate, reproxalap, is a topical treatment aimed at the signs and symptoms of dry eye disease, a large and competitive ophthalmology market. The pivotal moment came on March 17, 2026, when the FDA issued a Complete Response Letter, the third for reproxalap in dry eye, declining to approve the New Drug Application. The agency cited a lack of substantial evidence of efficacy, pointing to inconsistency across studies: one Phase 3 trial met its primary sign endpoint while a separate field trial did not, undermining confidence in the overall dataset. Shares collapsed roughly 70% on the news, falling from about $4.23 to near $1.37.

What Is Driving Attention Around ALDX?

The narrow decline in ALDX's most recent session does not stem from a single identifiable public catalyst; it is better read as continued Volatility in a stock still absorbing the March rejection. The dominant force pressuring the shares remains regulatory. After three Complete Response Letters, investors are weighing whether reproxalap can ever clear the FDA's efficacy bar. Aldeyra has said it does not believe additional Clinical Trials were requested and has pursued further dialogue with the agency, including a resubmission of the application and interactions disclosed in mid-2026 filings. That leaves the stock caught between a depressed valuation and an unresolved regulatory question.

Key Numbers and Company Position

The verified figures frame a company with time but no product revenue. Aldeyra reported roughly $70 million in cash as of December 31, 2025, which management has said funds operations into 2028, an unusually long runway for a micro-cap. The post-CRL crash from about $4.23 to $1.37 illustrates how binary regulatory outcomes can be. AbbVie holds an option agreement tied to reproxalap that the company has described as potentially worth up to $100 million upon FDA approval, underscoring the asset's value if the program succeeds. As of the latest snapshot, ALDX carried a market Capitalization near $90 million.

What Could Come Next?

The central catalyst is the regulatory path forward. Investors may be watching for the outcome of Aldeyra's FDA engagement, including any Type A meeting feedback, the status of the resubmitted NDA and a potential new action date. Progress or setbacks on that front would likely move the stock more than routine trading. Beyond dry eye, updates on reproxalap's other potential indications and on Aldeyra's broader RASP pipeline could influence sentiment, as could any decision by AbbVie regarding its option.

Risks to Watch

The risks are considerable and concentrated. Three consecutive Complete Response Letters signal deep FDA skepticism about reproxalap's efficacy evidence, and there is no guarantee the drug is ever approved for dry eye. A clinical-stage company with no marketed product depends on its cash cushion and could face financing or dilution pressure if the runway shortens or the pipeline needs funding. Competition in dry eye treatment is intense, and the stock's history of sharp moves highlights ongoing volatility.

Conclusion

Aldeyra Therapeutics sits at a regulatory crossroads. The March 2026 Complete Response Letter, the third for reproxalap, reset both the story and the share price, and the company's next chapter hinges on whether continued FDA dialogue can salvage an approval. With a multi-year cash runway, a partnered option from AbbVie and an unresolved application, ALDX offers a clear set of milestones to monitor. For now, the recent dip is minor next to the larger question of whether reproxalap can satisfy regulators.